# A Study of Relapse Prevention and the Effectiveness of Long-acting Injectable Risperidone and Quetiapine Tablets in the Treatment of Patients With Schizophrenia or Schizoaffective Disorder

> **NCT00216476** · PHASE3 · COMPLETED · sponsor: **Janssen-Cilag International NV** · enrollment: 753 (actual)

## Conditions studied

- Schizophrenia
- Psychotic Disorders

## Interventions

- **DRUG:** Aripiprazole
- **DRUG:** Risperidone Long Acting Injectable (LAI)
- **DRUG:** Quetiapine

## Key facts

- **NCT ID:** NCT00216476
- **Lead sponsor:** Janssen-Cilag International NV
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2004-10
- **Primary completion:** 2007-11
- **Final completion:** 2007-11
- **Target enrollment:** 753 (ACTUAL)
- **Last updated:** 2014-04-16


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00216476

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00216476, "A Study of Relapse Prevention and the Effectiveness of Long-acting Injectable Risperidone and Quetiapine Tablets in the Treatment of Patients With Schizophrenia or Schizoaffective Disorder". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT00216476. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*